Nicholas Weber
Clermont, FLNPI 1356769160
Payments from drug & device makers
What this record shows
AstraZeneca accounts for 81.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $1,049 and has fallen 90.0% since, to $105 in 2023.
Across 13 payments — averaging $99.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Biogen$134
- Takeda Pharmaceuticals U.S.A., Inc.$105
Across 126 payments — averaging $45,234 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.6M
- AbbVie$1.2M
- Biogen$701K
- E.r. Squibb & Sons, L.L.C.$559K
- Pfizer$484K
- Genentech, Inc.$61K
- plus $43K from 3 others
What the payments were for
- Travel & lodging$77260%
- Food & beverage$51540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $1,049 |
| Biogen | 1 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADUHELM$134
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.